 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Tarlige |
| Other names | DS-5565 |
| Routes of administration | By mouth |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H19NO2 |
| Molar mass | 209.289 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mirogabalin (brand nameTarlige; developmental code nameDS-5565) is agabapentinoid medication developed byDaiichi Sankyo.Gabapentin andpregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to theα2δ subunit of voltage-gated calcium channel (1 and2), but with significantly higher potency than pregabalin. It has shown promising results in Phase IIclinical trials for the treatment ofdiabetic peripheral neuropathic pain.[1][2]
Phase III trial results:
In Japan, the company submitted a marketing application for treatment ofperipheral neuropathic pain.[5] The medication was approved forneuropathic pain andpostherpetic neuralgia in Japan in January 2019.[6]
